July 2019 Bonus Mid-Year Issue
Volume 5, Issue 9
This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.
Table of Contents
July 2019 Bonus Mid-Year Issue
Modern Medicine and Modern Stoicism
One of the things I have found myself particularly struggling with as a fairly new attending is accepting that patients are free to make...
July 2019 Bonus Mid-Year Issue
The Spy Next Door?
Academic institutions and government organizations strive to prevent research espionage while maintaining open scientific collaborations
For decades, the U.S. has fostered international research collaborations with...
July 2019 Bonus Mid-Year Issue
Adding Pneumatic Compression to Heparin Therapy Does Not Reduce DVT in Critically Ill Patients
According to results from the PREVENT trial, adjunctive pneumatic compression plus pharmacologic thromboprophylaxis did not lower the risk of new lower-limb deep vein thrombosis...
Mixed Opinions on Quizartinib From the FDA and Japanese Regulators
After the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee decided against recommending approval of quizartinib for patients with relapsed/refractory FLT3-ITD acute...
Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...
If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma
According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...
Ibrutinib Plus Venetoclax Leads to High Rates of MRD Negativity in Frontline CLL
The combination of ibrutinib with venetoclax – two agents that have been approved for the treatment of chronic lymphocytic leukemia (CLL) – led to...
Daratumumab Combination Extends Progression-Free Survival for Transplant-Ineligible Myeloma
In patients with newly diagnosed multiple myeloma (MM) who were ineligible for autologous hematopoietic cell transplantation (AHCT), adding daratumumab to a regimen of lenalidomide...
FDA Approves First Anticoagulant for Pediatric Patients
The FDA approved dalteparin sodium, administered as a subcutaneous injection, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients (≥1 month).
Dalteparin...
Trump Administration Ends Fetal Tissue Research at NIH
In June, the Department of Health and Human Services (HHS) announced a new policy curtailing government-funded research that uses fetal tissue donated after elective...
Gilteritinib Outperforms Standard Chemotherapy in FLT3-Mutated AML, Regardless of Mutation Burden
According to an analysis from the phase III ADMIRAL trial, treatment with gilteritinib was associated with higher response rates and longer survival than chemotherapy...
Study Finds Urgent Need for Sickle Cell Disease Screening Among African Refugees in Italy
Most refugees who arrive at the Mediterranean coast of Italy and other southern European countries are leaving areas where sickle cell disease (SCD) is...
FDA Recalls Three Hematology Analyzers
The FDA issued a Class I recall of three hematology analyzers – Beckman Coulter DxH 800, DxH 600, and DxH 900 – after reports...
July 2019 Bonus Mid-Year Issue
AMG 420 Continues to Show Efficacy in Relapsed/Refractory Myeloma
In updated results from the first-in-human study of the bispecific T-cell engager (BITE) AMG 420, the agent continued to demonstrate clinical activity in patients...
Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis
In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm,...
Luteinizing Hormone Suppression Improves Post-Chemotherapy Hematopoietic Recovery in Patients With Leukemia
Treatment of leukemia with intensive chemotherapy increases patients’ risk of infection and bleeding due to myelosuppression, but according to results from a study presented...
Bispecific Antibody REGN1979 Shows Promising Efficacy in Relapsed/Refractory Non-Hodgkin Lymphomas
In a small phase I study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL), approximately half of patients responded to treatment with REGN1979, an anti-CD20...
Evaluating Rozanolixizumab in Primary Immune Thrombocytopenia
Rozanolixizumab, at doses ranging from 4 to 15 mg/kg, induced platelet responses in patients with primary immune thrombocytopenia (ITP), according to an interim analysis...
Polatuzumab Vedotin Combination Appears Effective in Relapsed/Refractory Follicular Lymphoma
Treatment with the CD79b-directed antibody drug conjugate polatuzumab vedotin, when combined with obinutuzumab and lenalidomide, was associated with high rates of complete response (CR)...
Dasatinib Plus Blinatumomab Increases Response and MRD Negativity in Ph-Positive Acute Lymphocytic Leukemia
Combining the second-generation tyrosine kinase inhibitor (TKI) dasatinib with the bispecific monoclonal antibody blinatumomab induced high response rates in adult patients with Philadelphia chromosome...
Gilteritinib Outperforms Standard Chemotherapy in FLT3-Mutated AML, Regardless of Mutation Burden
According to an analysis from the phase III ADMIRAL trial, treatment with gilteritinib was associated with higher response rates and longer survival than chemotherapy...
Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia
According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...
